Trial · NCT04163458
Outcomes54
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
1 to 20 of 54
Download this page as JSON| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Number of Fertilized (2 Pronuclei [2PN]) Oocytes | On Day 1 after oocyte retrieval (up to 23 days after start of stimulation) | Fertilized oocytes | MEAN | |
| SECONDARY | Positive Beta Human Chorionic Gonadotropin (βhCG) Rate | 10-14 days after blastocyst transfer (up to approximately 6 weeks after start of stimulation) | Participants | COUNT_OF_PARTICIPANTS | |
| SECONDARY | Clinical Pregnancy Rate | 5-6 weeks after blastocyst transfer (up to approximately 10 weeks after start of stimulation) | Participants | COUNT_OF_PARTICIPANTS | |
| SECONDARY | Ongoing Pregnancy Rate | 8-9 weeks after blastocyst transfer (up to approximately 13 weeks after start of stimulation) | Participants | COUNT_OF_PARTICIPANTS | |
| SECONDARY | Early Pregnancy Loss | 8-9 weeks after blastocyst transfer (up to approximately 13 weeks after start of stimulation) | Only participants who had a positive βhCG test were eligible. | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Follicular Development on Stimulation Day 6 | At stimulation Day 6 | Follicles | MEAN | |
| SECONDARY | Follicular Development on Last Day of Stimulation | At last day of stimulation (up to 20 stimulation days) | Follicles | MEAN | |
| SECONDARY | Serum Follicle-stimulating Hormone (FSH) Concentration | At Day 6, last day of stimulation (up to 20 stimulation days) and at oocyte retrieval (up to 22 days after start of stimulation) | Participants analyzed for this endpoint represent participants who were evaluable for this outcome measure. | IU/L | MEDIAN |
| SECONDARY | Serum Anti-Müllerian Hormone (AMH) Concentration | At the last day of stimulation (up to 20 stimulation days) and at end-of-trial (up to approximately 6 months from the start of screening) | Participants analyzed for this endpoint represent participants who were evaluable for this outcome measure. | pmol/L | MEDIAN |
| SECONDARY | Human Chorionic Gonadotropin (hCG) Concentration | At Day 6 and last day of stimulation (up to 20 stimulation days) | Participants analyzed for this endpoint represent participants who were evaluable for this outcome measure. | IU/L | MEDIAN |
| SECONDARY | Luteinizing Hormone (LH) Concentration | At Day 6 and last day of stimulation (up to 20 stimulation days) | Participants analyzed for this endpoint represent participants who were evaluable for this outcome measure. | IU/L | MEDIAN |
| SECONDARY | Progesterone (P4) Concentration | At Day 6 and last day of stimulation (up to 20 stimulation days) | Participants analyzed for this endpoint represent participants who were evaluable for this outcome measure. | ng/mL | MEDIAN |
| SECONDARY | Estradiol (E2) Concentration | At stimulation Day 6 and last day of stimulation (up to 20 stimulation days) | Participants analyzed for this endpoint represent participants who were evaluable for this outcome measure. | pg/mL | MEDIAN |
| SECONDARY | Number of Oocytes Retrieved | On day of oocyte retrieval (up to 22 days after start of stimulation) | Oocytes | MEAN | |
| SECONDARY | Number of Metaphase II (MII) Oocytes | On day of oocyte retrieval (up to 22 days after start of stimulation) | Only participants with Oocytes retrieved were eligible. | MII Oocytes | MEAN |
| SECONDARY | Fertilization Rate | On Day 1 after oocyte retrieval (up to 23 days after start of stimulation) | Only participants with Oocytes retrieved were eligible. | Percentage | MEAN |
| SECONDARY | Number of Blastocysts and Number of Good-Quality Blastocysts 5 Days After Oocyte Retrieval | On Day 5 after oocyte retrieval (up to 27 days after start of stimulation) | Blastocysts | MEAN | |
| SECONDARY | Total Gonadotropin Dose | Up to 20 stimulation days | IU | MEAN | |
| SECONDARY | Number of Stimulation Days | Up to 20 stimulation days | Days | MEAN | |
| SECONDARY | Proportion of Participants With Ovarian Hyperstimulation Syndrome (OHSS) | ≤9 days after triggering of final follicular maturation (early OHSS), >9 days after triggering of final follicular maturation until 21-28 days after last IMP dose or up to ongoing pregnancy 8-9 weeks after transfer in pregnant participants (late OHSS) | Percentage of participants | NUMBER |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT04163458/outcomes